| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Christopher Evernden, Irene Giang, Mariah Anderso. The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia. The mental health clinician. vol 11. issue 5. 2021-10-09. PMID:34621608. |
the use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia. |
2021-10-09 |
2023-08-13 |
Not clear |
| Nora Palomar-Ciria, Marta Migoya-Borja, Fanny Cegla-Schvartzman, Santiago Ovejero, Raquel Alvarez-Garcia, Hugo J Bello, Enrique Baca-Garcí. Early administration of aripiprazole long-acting injectable in acute inpatients with schizophrenia: a clinical report. International clinical psychopharmacology. vol 36. issue 2. 2021-10-04. PMID:33492014. |
early administration of aripiprazole long-acting injectable in acute inpatients with schizophrenia: a clinical report. |
2021-10-04 |
2023-08-13 |
Not clear |
| Nora Palomar-Ciria, Marta Migoya-Borja, Fanny Cegla-Schvartzman, Santiago Ovejero, Raquel Alvarez-Garcia, Hugo J Bello, Enrique Baca-Garcí. Early administration of aripiprazole long-acting injectable in acute inpatients with schizophrenia: a clinical report. International clinical psychopharmacology. vol 36. issue 2. 2021-10-04. PMID:33492014. |
fifty-one patients suffering an acute episode of schizophrenia and treated with aripiprazole long-acting injectable (alai) were chosen to elaborate an observational study in two in-patient units in spain, in order to examine the effects of early administration during a hospital admission. |
2021-10-04 |
2023-08-13 |
Not clear |
| Nobuhisa Kanahara, Masayuki Takase, Tsuyoshi Sasaki, Masanori Honma, Yasutaka Fujita, Shigenori Tadokoro, Hitoshi Suzuki, Hiroshi Yamanaka, Shingo Noda, Satoshi Yanahashi, Takahisa Saiga, Naoya Komatsu, Takeshi Simoyama, Masaomi Iy. The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study. International clinical psychopharmacology. vol 35. issue 6. 2021-09-28. PMID:32868522. |
the effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study. |
2021-09-28 |
2023-08-13 |
Not clear |
| Nobuhisa Kanahara, Masayuki Takase, Tsuyoshi Sasaki, Masanori Honma, Yasutaka Fujita, Shigenori Tadokoro, Hitoshi Suzuki, Hiroshi Yamanaka, Shingo Noda, Satoshi Yanahashi, Takahisa Saiga, Naoya Komatsu, Takeshi Simoyama, Masaomi Iy. The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study. International clinical psychopharmacology. vol 35. issue 6. 2021-09-28. PMID:32868522. |
the present study was conducted to examine whether very slowly switching to aripiprazole could help patients with schizophrenia with dopamine supersensitivity while avoiding rebound psychosis. |
2021-09-28 |
2023-08-13 |
Not clear |
| Minami Tasaki, Norio Yasui-Furukori, Saaya Yokoyama, Masataka Shinozaki, Norio Sugawara, Kazutaka Shimod. Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels. Neuropsychopharmacology reports. vol 41. issue 3. 2021-09-21. PMID:34189861. |
hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels. |
2021-09-21 |
2023-08-13 |
Not clear |
| Debby Handayati Harahap, Carla Raymondalexas Marchira, Eti Nurwening Solikhah, Dicky Moch Riza. The role of aripiprazole in improvement of penile erection in schizophrenia patients with erectile dysfunction. Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina. vol 18. issue 2. 2021-09-07. PMID:33871221. |
the role of aripiprazole in improvement of penile erection in schizophrenia patients with erectile dysfunction. |
2021-09-07 |
2023-08-13 |
Not clear |
| Debby Handayati Harahap, Carla Raymondalexas Marchira, Eti Nurwening Solikhah, Dicky Moch Riza. The role of aripiprazole in improvement of penile erection in schizophrenia patients with erectile dysfunction. Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina. vol 18. issue 2. 2021-09-07. PMID:33871221. |
aim to provide evidence regarding the effectiveness of aripiprazole in improving penile erection with a therapeutic strategy of add-on or switching therapy in patients with schizophrenia. |
2021-09-07 |
2023-08-13 |
Not clear |
| Debby Handayati Harahap, Carla Raymondalexas Marchira, Eti Nurwening Solikhah, Dicky Moch Riza. The role of aripiprazole in improvement of penile erection in schizophrenia patients with erectile dysfunction. Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina. vol 18. issue 2. 2021-09-07. PMID:33871221. |
pubmed, cochrane, clinical key, proquest, ebscohost, and sciencedirect were searched for any design study that evaluated aripiprazole only or versus control (placebo or other antipsychotic) for erectile dysfunction in patients with schizophrenia. |
2021-09-07 |
2023-08-13 |
Not clear |
| Debby Handayati Harahap, Carla Raymondalexas Marchira, Eti Nurwening Solikhah, Dicky Moch Riza. The role of aripiprazole in improvement of penile erection in schizophrenia patients with erectile dysfunction. Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina. vol 18. issue 2. 2021-09-07. PMID:33871221. |
conclusion aripiprazole was effective to improve penile erectile function in patients with schizophrenia. |
2021-09-07 |
2023-08-13 |
Not clear |
| Hiroyuki Fujiyama, Hiroko Sugawara, Teppei Kanno, Kazuhiro Kawahara, Hibiki Tanaka, Ryuji Fukuhara, Shuken Boku, Minoru Takebayash. Combination therapy of brexpiprazole and aripiprazole for an adolescent patient with a first episode of schizophrenia: A case report. Psychiatry and clinical neurosciences. vol 74. issue 12. 2021-09-06. PMID:32909325. |
combination therapy of brexpiprazole and aripiprazole for an adolescent patient with a first episode of schizophrenia: a case report. |
2021-09-06 |
2023-08-13 |
Not clear |
| Li Qian, Liao Xuemei, Li Jitao, Su Yun'Ai, Si Tianme. Dose-Dependent Efficacy of Aripiprazole in Treating Patients With Schizophrenia or Schizoaffective Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in psychiatry. vol 12. 2021-08-31. PMID:34456770. |
dose-dependent efficacy of aripiprazole in treating patients with schizophrenia or schizoaffective disorder: a systematic review and meta-analysis of randomized controlled trials. |
2021-08-31 |
2023-08-13 |
Not clear |
| Paula Soria-Chacartegui, Gonzalo Villapalos-García, Pablo Zubiaur, Francisco Abad-Santos, Dora Kolle. Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone. Frontiers in pharmacology. vol 12. 2021-08-03. PMID:34335273. |
olanzapine, aripiprazole and risperidone are atypical antipsychotics or neuroleptics widely used for schizophrenia treatment. |
2021-08-03 |
2023-08-13 |
Not clear |
| Anna Maria Szota, Izabela Radajewska, Aleksander Stanisław Araszkiewic. Atypical Neuroleptic Malignant Syndrome: Case Reports and Diagnostic Challenges. Journal of psychoactive drugs. 2021-08-03. PMID:34340640. |
atypical neuroleptic malignant syndrome was found to develop mainly in male patients suffering from schizophrenia (14 cases) and bipolar disorder (2), and was induced by clozapine (6 cases), olanzapine (5 cases), aripiprazole and quetiapine (4 cases). |
2021-08-03 |
2023-08-13 |
Not clear |
| Kunal Maini, Haley Gould, Jessica Hicks, Fatima Iqbal, James Patterson, Amber N Edinoff, Elyse M Cornett, Adam M Kaye, Omar Viswanath, Ivan Urits, Alan D Kay. Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review. Neurology international. vol 13. issue 3. 2021-07-24. PMID:34287335. |
aripiprazole lauroxil, a novel injectable long-acting antipsychotic treatment for adults with schizophrenia: a comprehensive review. |
2021-07-24 |
2023-08-13 |
Not clear |
| Kunal Maini, Haley Gould, Jessica Hicks, Fatima Iqbal, James Patterson, Amber N Edinoff, Elyse M Cornett, Adam M Kaye, Omar Viswanath, Ivan Urits, Alan D Kay. Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review. Neurology international. vol 13. issue 3. 2021-07-24. PMID:34287335. |
this is a comprehensive review of the literature regarding the use of aripiprazole lauroxil for schizophrenia. |
2021-07-24 |
2023-08-13 |
Not clear |
| Kunal Maini, Haley Gould, Jessica Hicks, Fatima Iqbal, James Patterson, Amber N Edinoff, Elyse M Cornett, Adam M Kaye, Omar Viswanath, Ivan Urits, Alan D Kay. Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review. Neurology international. vol 13. issue 3. 2021-07-24. PMID:34287335. |
this review presents the background, evidence, and indications for using aripiprazole lauroxil to treat schizophrenia in the context of current theories on the development of schizophrenia. |
2021-07-24 |
2023-08-13 |
Not clear |
| Ilda Bidollari, Alexa Vasios, Amy Claxto. Safety and Tolerability of Aripiprazole Lauroxil 2-Month Formulation With 1-Day Initiation for Treatment of Schizophrenia in the ALPINE Study. CNS spectrums. vol 26. issue 2. 2021-07-23. PMID:34127093. |
safety and tolerability of aripiprazole lauroxil 2-month formulation with 1-day initiation for treatment of schizophrenia in the alpine study. |
2021-07-23 |
2023-08-13 |
Not clear |
| Ilda Bidollari, Alexa Vasios, Amy Claxto. Safety and Tolerability of Aripiprazole Lauroxil 2-Month Formulation With 1-Day Initiation for Treatment of Schizophrenia in the ALPINE Study. CNS spectrums. vol 26. issue 2. 2021-07-23. PMID:34127093. |
evaluate safety and tolerability of an aripiprazole lauroxil (al) 2-month regimen using 1-day initiation in patients hospitalized for acute exacerbation of schizophrenia and transitioned to outpatient care. |
2021-07-23 |
2023-08-13 |
Not clear |
| Henry Nasrallah, David Walling, Peter J Weiden, Yangchun Du, Baiyun Yao, Sergey Yagoda, Amy Claxto. Aripiprazole Lauroxil 2-Month Formulation With 1-Day Initiation for Acute Schizophrenia: ALPINE Exploratory Efficacy and Patient-Reported Outcomes. CNS spectrums. vol 26. issue 2. 2021-07-23. PMID:34127096. |
aripiprazole lauroxil 2-month formulation with 1-day initiation for acute schizophrenia: alpine exploratory efficacy and patient-reported outcomes. |
2021-07-23 |
2023-08-13 |
Not clear |